| Amgen Switzerland AG - Wezenla 130 mg/26 ml, Konzentrat zur Herstellung einer Infusionslösung | | 70187 | | 01 | | Wezenla 130 mg/26 ml | | Konzentrat zur Herstellung einer Infusionslösung | | L04AC05 | | Ustekinumab | | 23.07.2025 | | |
| | Composition | | ustekinumabum 130 mg, saccharum, histidinum, histidini hydrochloridum monohydricum, methioninum, polysorbatum 80, dinatrii edetas, natrii hydroxidum, aqua ad iniectabile q.s. ad solutionem pro 26 ml, natrium 0.097 mg. | | Packungsbestandteile | | Concentrate for infusion | | | | | | | | Active Agent | Dose |
|---|
| Ustekinumabum | 130mg / 26ml |
| | BAG: Active Agent | Dose |
|---|
| Ustekinumabum | 130 mg |
| | | | Inactive agents |
|---|
| Dinatrii Edetas | | Histidin Hydrochloride Monohydrate | | Histidine | | Methionine | | Sodium Hydroxide | | Polysorbatum 80 | | Saccharum |
| |
| | Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 001 | | 1401.06 | 1540.15 | B | SL | No |
|
|
